This Phase II trial is trying to understand the effectiveness of a new targeted therapy (ARX788) in people with HER2-positive metastatic breast cancer who have not responded to other targeted therapies (T-DM1, T-DXd, Tucatinib).
This trial is treating patients with HER2+ metastatic breast cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens
This is a Phase II, open-label trial with one experimental arm, designed to assess the anti-cancer activity and safety of ARX788 in HER2+ metastatic breast cancer patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. Participants will receive ARX788 every 4 weeks (Q4W) by intravenous infusion.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More